Main menu
Click categories to expand
A-Z listingplugin-autotooltip__plain plugin-autotooltip_bigA-Z listing
This is an alphabetical index of all content pages.
Other categories
Utilities
Also see
Importance Ratings
News
Legal
Donate/Sponsor
Curator's rationale
AI Policy
Twitter feed ð•
Feeds + s.e.o. etc.
rss / xml feed 
sitemap file
A-Z listing (archived)
Levetiracetam, sold under brand names of Keppra, Elepsia, Epictal, Lenerve, Levepsy, Torleva (and many others) is a prescription-only anticonvulsant medication forepilepsyplugin-autotooltip__plain plugin-autotooltip_bigEpilepsy
"Epilepsy is a chronic noncommunicable disease of the brain that affects around 50 million people worldwide. It is characterized by recurrent seizures, which are brief episodes of involuntary movement that may involve a part of the body (partial) or the entir…. It is used for partial onset, myoclonic, or tonic-clonic seizures. It is taken by mouth as an immediate or extended release formulation. There are currently more than 6 million prescriptions per year in the US alone.
Its mechanism of action is currently unknown.
See: Mechanisms of Levetiracetam in the Control of Status Epilepticus and Epilepsy 
Frontiers in Neurology 2014; 5: 11.
Ideas for new topics, and suggested additions / corrections for older ones, are always welcome.
If you have skills or interests in a particular field, and have suggestions for Wikenigma, get in touch !
Or, if you'd like to become a regular contributor . . . request a login password. Registered users can edit the entire content of the site, and also create new pages.
( The 'Notes for contributors' section in the main menu has further information and guidelines etc.)
You are currently viewing an auto-translated version of Wikenigma
Please be aware that no automatic translation engines are 100% accurate, and so the auto-translated content will very probably feature errors and omissions.
Nevertheless, Wikenigma hopes that the translated content will help to attract a wider global audience.
DOKUWIKI IMPLEMENTATION DESIGN BY UNIV.ORG.UK DECEMBER 2023